Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts

By /

Both Novo Nordisk and Eli Lilly are eyeing regulatory advancements for their obesity blockbusters as the European Association for the Study of Diabetes’ annual conference continues this week.

Scroll to Top